It is increasingly evident that genes known to perform critical roles during early embryogenesis, particularly during stem cell renewal, pluripotentiality and survival, are also expressed during the development of cancer. In this regard, oncogenesis may be considered as the recapitulation of embryogenesis in an inappropriate temporal and spatial manner. The epidermal growth factor-Cripto-1/FRL1/cryptic family of proteins consists of extracellular and cell-associated proteins that have been identified in several vertebrate species. During early embryogenesis, epidermal growth factor-Cripto-1/FRL1/ cryptic proteins perform an obligatory role as coreceptors for the transforming growth factor-beta subfamily of proteins, which includes Nodal. Cripto-1 has also been shown to function as a ligand through a Nodal/Alk4-independent signaling pathway that involves binding to glypican-1 and the subsequent activation through src of phosphoinositol-3 kinase/Akt and ras/mitogen-activated protein kinase intracellular pathways. Expression of Cripto-1 is increased in several human cancers and its overexpression is associated with the development of mammary tumors in mice. Here, we review the role of Cripto-1 during embryogenesis, cell migration, invasion and angiogenesis and how these activities may relate to cellular transformation and tumorigenesis. We also briefly discuss evidence suggesting that Cripto-1 may be involved in stem cell maintenance.
Introduction
Embryonic genes are important in regulating asymmetric cell division, pluripotentiality and/or in maintaining cellular and tissue-specific niches that are necessary for stem cell survival (Kopper and Hajdu, 2004; Ohlstein et al., 2004; Sell, 2004) . Genetic mutations within stem cells or alterations in signaling pathways within the stem cell niche are almost certainly central to the early appearance of premalignant cells. Stem cells, therefore, represent desirable targets for the development of future cancer therapies (Reya et al., 2001; Beachy et al., 2004) . Growth factors that are important in development, oncogenesis and stem cell self-renewal include members of the Hedgehog (Hh), Wnt, Notch, transforming growth factor beta (TGFb/ Activin/Nodag/BMP) and epidermal growth factorCripto-1/FRL1/cryptic (EGF-CFC) superfamilies Shen and Schier, 2000; Kodjabachian, 2001 ; Kleber and Sommer, 2004; Nelson and Nusse, 2004; Tabata and Takei, 2004) .
Identification and structure of the EGF-CFC gene family
Human Cripto-1 (CR-1), also known as teratocarcinoma-derived growth factor-1 (TDGF-1), is a member of the EGF-CFC protein family . Orthologous genes have been identified in the mouse (Cr-1) (Dono et al., 1993) , chicken (Colas and Schoenwolf, 2000) , zebrafish (Zhang et al., 1998) and Xenopus (FRL1) (Kinoshita et al., 1995) . Related genes include mouse cryptic (Cfc1) and human cryptic (CFC1) (Shen et al., 1997; Bamford et al., 2000; Shen and Schier, 2000; de la Cruz et al., 2002) . EGF-CFC family members contain an NH 2 -terminal signal peptide, a modified EGF-like region, a conserved cysteine-rich domain (CFC motif) and a short hydrophobic COOH-terminus that contains additional sequences for glycosylphosphatidylinositol (GPI) cleavage and attachment (Minchiotti et al., 2000) (Figure 1 ). In addition, all EGF-CFC proteins contain a consensus O-linked fucosylation site within the EGF-like motif that is necessary for their ability to function as coreceptors for the TGFb-related proteins, Nodal or Vg1/GDF-1 (Schiffer et al., 2001; Yan et al., 2002) . Most of the EGF-CFC proteins are cell-associated glycoproteins that contain from 171 to 202 amino acids and that range from 18 to 21 kDa in size. However, the native mouse and human Cripto-1 proteins are 24, 28 and 36 kDa in size and additional proteins ranging from 14 to 60 kDa have also been identified and are the result of differential glycosylation at N-and O-linked asparagine and serine residues Kenney et al., 1996; Seno et al., 1998; Niemeyer et al., 1999; Minchiotti et al., 2000; Schiffer et al., 2001) . The mouse Cr-1 protein can be released by treatment of cells with phosphatidylinositol-specific phospholipase C (PI-PLC) (Minchiotti et al., 2000) . Removing the COOH-terminal stretch of residues where GPI linkage occurs generates soluble forms of biologically active mouse and human Cripto-1 (Xu et al., 1999; Minchiotti et al., 2001; Bianco et al., 2002b Bianco et al., , 2003 Yan et al., 2002) . Full activity requires the presence of a peptide containing only an intact EGF domain and CFC domain Yan et al., 2002) . However, whether there are significant qualitative and/or quantitative differences in the biological activities that are regulated by Cripto-1 between the soluble versus cell-associated forms is not yet known since Cripto-1 can function both as a coreceptor in cis (autocrine/cell-autonomous) and as ligand in trans (paracrine/cell-nonautonomous) (Yan et al., 2002) .
Function of Cripto-1 during embryonic development
Genetic studies in zebrafish and mice have defined an essential role for Nodal that functions through Cripto-1 in the formation of the primitive streak, patterning of the Anterior/Posterior axis (A/P) and specification of mesoderm and endoderm (mesoendoderm) during gastrulation, whereas later in embryogenersis Nodal functions through cryptic in the establishment of Left/Right (L/R) asymmetry of developing organs (Ding et al., 1998; Yan et al., 1999; Schier and Shen, 2000; Hamada et al., 2002; Schier, 2003) . Cr-1-null mice (Cr-1 À/À ) die at day 7.5 due to their inability to gastrulate and form appropriate germ layers (Liguori et al., 1996; Ding et al., 1998) . Nodal, which functions through Cripto-1, cooperates with wnt3 in the mouse in initiating the specification of mesoderm and endoderm formation and in regulating the development of dorsal and anterior mesoderm and head structures (Harland and Gerhart, 1997; Beddington and Robertson, 1999; Liu et al., 1999; Thisse et al., 2000; Kodjabachian, 2001; Robb and Tam, 2004) . In contrast, Cripto-1 in conjunction with Fgf8 and brachyury are important for initiating and maintaining the migration of mesodermal cells through the primitive streak (Conlon and Smith, 1999; Ciruna and Rossant, 2001; Griffin and Kimelman, 2003; Warga and Kane, 2003) . Mutations in zebrafish of the Cripto-1 ortholog, one-eyed pinhead (oep) result in cyclopia, an absence of head and trunk mesoderm, loss of prechordal plate and ventral neuroectoderm, impairment of gastrulation movements, loss of A/P axis positioning and left/right laterality defects (Zhang et al., 1998; Gritsman et al., 1999) . One-eyed pinhead, like mouse Cr-1, is absolutely required for the migration of mesendoderm cells through the primitive streak (Warga and Kane, 2003) . Mutations of oep effectively block the ability of epiblast cells to migrate and induce a more cohesive interaction between these cells. This effect is independent of the two zebrafish Nodal-related genes, squint (Sqt) and Cyclops (Cyc), suggesting that these phenotypes are unique to oep.
Mouse Cr-1 is expressed in the precardiac mesoderm and performs an essential role during the early stages of cardiac lineage specification and differentiation (Dono et al., 1993) . Homozygous knockout of the Cr-1 gene (Cr-1 À/À ) in pluripotential embryonic stem (ES) cells impairs their ability to spontaneously differentiate in vitro into cardiomyocytes (Parisi et al., 2003) without affecting the ability of ES cells to differentiate into other cell types (Xu et al., 1998) . In fact, Cr-1 À/À ES cells actually show extensive neural differentiation in vitro and in vivo suggesting that neuroectodermal differentiation is the preferred default pathway that occurs in the absence of Cr-1 expression (Parish et al., 2005; Sonntag et al., 2005) . Chimeric embryos that were generated between wild-type and Cr-1 À/À ES cells in vitro were normal indicating that Cr-1 produced by the wild-type host cells could rescue the mutant phenotype in a paracrine manner (Xu et al., 1998) . Germline disruption of Cr-1 in Cr-1 À/À embryos results in the formation of embryos that possess a head without a trunk demonstrating that there is a severe deficiency in embryonic mesoderm and endoderm without a loss of anterior neuroectoderm formation (Xu et al., 1999) .
Intracellular signal transduction pathways that mediate Cripto-1 activity
Cripto-1 is involved in the activation of several different signaling pathways during embryonic development and cellular transformation . The major signaling pathways activated by Cripto-1 are a Nodal/ ALK4/ALK7/Smad-2 signaling pathway and a Glypican-1/ c-Src/MAPK/AKT signaling pathway. (Schier, 2003) . Biochemical evidence has demonstrated a direct interaction between mouse Cr-1 and ALK4 in Xenopus oocytes and this interaction is necessary for Nodal to bind to the ALK4/ActRIIB receptor complex and to stimulate Smad-2 phosphorylation and activation Bianco et al., 2002a) . Cripto-1 can also directly interact with serine threonine kinase receptor ALK7 enhancing the ability of ALK7 to respond to Nodal (Reissmann et al., 2001) . However, Nodal can directly bind ALK7 in the absence of Cripto-1, although Cripto-1 significantly enhances its signaling activity (Reissmann et al., 2001) . Site-directed mutagenesis experiments have shown that Cripto-1 interacts with Nodal through the EGF-like domain, while the CFC domain mediates binding of Cripto-1 to ALK4 . In addition to functioning as a coreceptor for Nodal, Cr-1 has been shown to mediate signaling of other TGFb ligands, such as Activin and Xenopus Vg1 and its ortholog in mouse GDF1 (Cheng et al., 2003) . Similar to Nodal, Vg1 and GDF1 can bind to ALK4/ActRIIB receptor complex only in the presence of EGF-CFC coreceptors. In contrast, binding of CR-1 to Activin can inhibit Activin signaling in mammalian cells Gray et al., 2003) . In this regard, Adkins et al. have demonstrated that CR-1 interacts with Activin B through the CFC domain, sequestering Activin B from a functional ALK4/ ActRIIB receptor complex and blocking its ability to function as an inhibitor of cell growth in cancer cells. Therefore, antagonism of Activin signaling by CR-1 may represent an additional mechanism used by CR-1 to promote tumorigenesis. In addition to being EGF-CFC-dependent, Nodal signaling is regulated by several antagonists that function at different levels. Tomoregulin-1, Lefty A and B and Antivin can antagonize Nodal signaling through EGF-CFC coreceptors. In this regard, the transmembrane protein Tomoregulin-1 inhibits Nodal signaling in Xenopus embryos through interaction with the CFC domain of CR-1 (Harms and Chang, 2003) . Furthermore, Tomoregulin-1, through its EGFlike domain, can specifically bind with low affinity to the tyrosine kinase receptor erbB-4 (Uchida et al., 1999) . Since CR-1 can indirectly increase the tyrosine phosphorylation of erbB-4 in several mouse and human mammary epithelial cells, interaction between CR-1 and Tomoregulin-1 might explain erbB-4 trans-phosphorylation by CR-1 in mammalian cells . The Lefty/Antivin subfamily has also been shown to antagonize Nodal and Vg1/GDF1 signalings through a direct interaction with EGF-CFC coreceptors (Chen and Shen, 2004) . Similarly, Xantivin, a Lefty-related protein in Xenopus, interacts directly with Xenopus FRL-1 and CR-1, leading to inhibition of Nodal signaling (Tanegashima et al., 2004 
Glypican-1/c-Src/MAPK/AKT signaling pathway
Our lab has previously demonstrated that CR-1 can activate the ras/raf/MAPK and PI3-K/AKT/GSK-3b signaling pathways Kannan et al., 1997; Ebert et al., 1999; Bianco et al., 2004) . Interestingly, activation of these signaling pathways can be achieved with a soluble GPI-truncated CR-1 recombinant protein Bianco et al., 2002b) . Since soluble CR-1 has been found to be secreted in the conditioned medium of several human carcinoma cell lines, it is possible that a functional soluble isoform of CR-1 is naturally cleaved from the cell membrane Minchiotti et al., 2000; Normanno et al., 2004) . Activation of these two intracellular pathways is independent of Nodal and ALK4, since CR-1 can stimulate MAPK and AKT phosphorylation in EpH4 mouse mammary epithelial cells and MC3T3-C1 osteoblast cells that lack ALK4 and Nodal expression, respectively (Bianco et al., 2002a) . Furthermore, activation of these two intracellular pathways occurs through a direct binding of CR-1 to Glypican-1, a membrane-associated heparan sulfate proteoglycan (HSPG) that functions as a coreceptor for several different growth factors (i.e. Wnts, FGF, HB-EGF) . Binding of CR-1 to Glypican-1 activates the cytoplasmic tyrosine kinase cSrc, triggering the MAPK and AKT signaling pathways . Since MAPK and AKT signaling pathways have been involved in regulating cell proliferation and survival, CR-1 might be involved in the pathogenesis of human cancer through the inappropriate activation of these two signaling pathways independently of Nodal and ALK4. CR-1 has also been shown to function during development through an FGFR-1 signaling pathway. In Xenopus oocytes and in yeast, Xenopus FRL1 can indirectly increase the phosphorylation of Xenopus FGFR-1 (Kinoshita et al., 1995) . However, no direct binding between FGFR-1 and FRL1 could be detected. Finally, several findings suggest a potential interaction of the CR-1 signaling pathway with the wnt/b-catenin/Lef-1 signaling pathway. In fact, Cr-1 has been identified by microarray analysis as a primary target gene in the wnt/b-catenin signaling pathway during embryonic development (Morkel et al., 2003) . More recently, FRL1 and mouse Cr-1 have been found to function as coreceptors for wnt-11 by binding directly to Wnt-11, providing a link between the EGF-CFC proteins and wnt family members (Tao et al., 2005) . Interestingly, in Xenopus, glypican-4 physically interacts with Wnt-11 suggesting that both glypican-4 and FRL1 are involved in regulating Wnt signaling (Ohkawara et al., 2003) . , 1997) . This inhibitory effect of CR-1 on b-casein expression in response to DIP is not unique to this mouse mammary epithelial cell line, since a similar inhibitory effect on b-casein expression in the presence of DIP is observed in CID-9 overexpressing QJ;Cr-1 (Niemeyer et al., 1998) . In addition, CR-1 modulates expression of other milk proteins in response to lactogenic hormones in primary mouse mammary explant cultures established from midpregnant mice . In this regard, concurrent treatment with DIP plus CR-1 significantly impairs DIP-induced expression of b-casein and whey acidic protein (WAP) in mammary explant cultures. The ability of CR-1 to block lactogenic hormone-induced expression of b-casein is mediated through a rasdependent, PI3-K-dependent pathway . This inhibitory effect of CR-1 on milk protein expression may be biologically significant since endogenous Cr-1 expression is upregulated in mouse mammary epithelial cells during pregnancy and lactation and soluble CR-1 protein is secreted in human milk .
Regulation of angiogenesis
We have recently demonstrated that human CR-1, in addition to regulating cell proliferation, survival and transformation, plays an essential role also in the multistep process of tumor angiogenesis . In fact, CR-1 has a strong angiogenic activity in vitro in cultured human umbilical endothelial cells (HUVECs). CR-1 enhances proliferation of HUVECs in a dose-dependent manner, stimulates their migration and invasion and induces formation of vascular-like structures on Matrigel. In addition, the chemotactic activity of CR-1 in HUVEC is mediated by c-Src and PI3-K/AKT signaling pathways. The angiogenic activity of CR-1 in endothelial cells is not dependent on the autocrine production of VEGF, since a specific VEG-FRI inhibitor does not block CR-1 angiogenic activity in vitro in HUVECs. In vivo, recombinant CR-1 protein induces microvessel formation in silicone cylinders filled with Matrigel and microvessel formation is strongly inhibited with a blocking anti-CR-1 monoclonal antibody (A8.G3.5), suggesting that CR-1 directly modulates angiogenesis. Finally, overexpression of CR-1 in MCF-7 human breast cancer cells enhances tumor neovascularization in a xenograft model.
Regulation of cellular migration and invasion by Cripto-1
Overexpression of Cr-1 in the mouse EpH4 mammary epithelial cells caused not only an increase in cell proliferation and anchorage-independent growth in soft agar but formation of duct-like structures when grown in collagen type I matrix and increased chemotaxis and migration when these cells were cultured on plastic or on porous filters coated with extracellular matrix proteins . The effects of Cr-1 in EpH4 cells was the first study which suggested that Cr-1 may play a role in inducing epithelial to mesenchymal transition (EMT) of mammary epithelial cells. Similarly, human MCF-7 breast cancer cells, which overexpress CR-1 in addition to acquiring higher proliferation rates in serum-free medium, increased colony formation in soft agar and increased resistance to anoikis also showed increased invasion through matrix-coated membranes as demonstrated by Boyden chamber invasion assay . Further evidence of the role that CR-1 might play in the induction of EMT comes from a recent study where the expression of markers that characteristically define EMT was investigated in mammary gland hyperplasias and tumors from MMTV-CR-1 transgenic mice and in HC-11/Cr-1 cells . During EMT, intercellular contacts between epithelial cells are lost due to decreased E-cadherin expression and disruption of the adherens junction complex as cells become less adhesive and potentially more motile (Boyer et al., 2000; Thiery, 2002) . E-cadherin expression was significantly decreased in tissue extracts from the mammary tumor lesions that express the CR-1 transgene and in extracts from HC-11/Cr-1 cells. Furthermore, the zinc-finger repressor transcription factor snail, which is known to downregulate or interfere with the normal expression of E-cadherin (Savagner, 2001) , was detected, by RT-PCR and Western blot analysis, at significantly higher levels in MMTV-CR-1 mammary tumor lesions and HC-11/Cr-1 cells as compared to control nontumorigenic mammary tissue and HC-11 wild-type cells, respectively . Expression of the mesenchyme cell cytoskeleton component, vimentin, is also increased in epithelial cells and tumors during EMT (Casaroli-Marano et al., 1999; Dandachi et al., 2001; Ackland et al., 2003) . Overexpression of CR-1 in human cervical carcinoma cells was associated with the increased expression of vimentin in these cells as they exhibited increased migration and invasion through matrix-coated membranes suggesting that CR-1-induced vimentin expression may contribute to a more aggressive phenotype of cervical carcinoma . Expression for vimentin was also increased in extracts from mammary gland hyperplasias and tumors from
Cripto-1: a modulator during embryogenesis and oncogenesis L Strizzi et al MMTV-CR-1 transgenic mice and from HC-11/Cr-1 cells. In addition, mammary tumors from the MMTV-CR-1 transgenic mice and HC-11/Cr-1 cells showed increased expression of active c-Src, focal adhesion kinase (FAK) and AKT . These signaling molecules can be activated during EMT and may play a role in increasing tumor cell migration and invasion (Thiery and Chopin, 1999) . Interestingly, mammary tumors from the MMTV-CR-1 transgenic mice and HC-11/Cr-1 cells were found to express the inactive form of glycogen synthease kinase 3 beta (GSK3b) as well as the active form of b-catenin. During wnt signaling, GSK-3b is inactivated by phosphorylation causing accumulation of nonphosphorylated b-catenin which translocates to the nucleus in a complex with Tcf/ Lef-1 and functions as a transcription factor activating genes involved in increased cell survival, proliferation and migration such as, c-myc, cyclin-D1, snail and slug (Polakis, 2000) . These data suggest that Cripto-1 may play a role in the regulation of cellular migration and invasion possibly through crosstalk with the Wnt signaling pathway (Figure 2) .
Role of Cripto-1 in transformation and cancer

In vitro transformation of cells by Cripto-1
The first in vitro study suggesting a potential role for Cripto-1 during cell transformation involved transfection of human CR-1 into NIH3T3 cells which induced morphological changes and colony formation of these cells when grown in monolayer (Ciccodicola et al., 1989) . When full-length CR-1 DNA was transfected into immortalized mouse NOG-8 mammary epithelial cells, those cells that expressed CR-1 were able to form colonies in soft agar and exhibited anchorage-independent growth in soft agar as compared to the neotransfected NOG-8 cells . Similarly, overexpression of CR-1 cDNA in normal rat fibroblasts was shown to induce growth of these cells in soft agar and exogenous recombinant CR-1 protein was shown to stimulate cell proliferation of differentiated and undifferentiated embryonal carcinoma cells (Su et al., 1993; Baldassarre et al., 1997) . Further support for transforming potential of Cripto-1 stems from studies showing increased expression of CR-1 in cells transformed by different oncogenes. For instance, overexpression of Cr-1 mRNA was detected in tumorigenic and metastatic Ha-rastransformed rat CREF embryo fibroblasts (Su et al., 1993) . Interestingly, in these cells, reversion of the transformed phenotype of the Ha-ras-transformed cells by overexpression of a Krev-1 ras suppressor gene resulted in a loss of expression of Cr-1. This suggests that Cr-1 may play a role in ras-induced CREF cell transformation. Cripto-1 was also found to be overexpressed in K-ras-transformed FRLT-5 rat thyroid epithelial cells which show TSH-independent growth capability (Mincione et al., 1998) . Also v-ras/Smad-7-transformed keratinocytes develop skin tumors that overexpress Cr-1 (Liu et al., 2003) , suggesting that Smad-7-induced tumor formation may require upregulation of Cr-1 and other EGF-related peptides.
In concert with Cripto-1 cellular transforming potential, it appears that Cripto-1 levels may affect cell differentiation. Mouse CID-9 mammary epithelial cells are derived from mammary glands of 14.5-day pregnant mice and normally express Cr-1 (Niemeyer et al., 1998) . When these cells are treated with lactogenic hormones and prolactin and are cultured on extracellular matrix substrates, they form differentiated polarized epithelial structures called mammospheres and express the milk protein b-casein and Cr-1. This suggests that hormones released during pregnancy may be involved in the regulation of Cr-1 expression. When CID-9 cells overexpress Cr-1, they show significantly higher proliferation rates, increased colony formation in soft agar and cell survival, but no longer form mammospheres and show reduced expression of b-casein. Conversely, if undifferentiated human or mouse teratocarcinoma cells are induced to differentiate by treatment with retinoic acid, expression of Cripto-1 is significantly reduced (Ciccodicola et al., 1989) . These data suggest that increased CR-1 levels may negatively affect cell Figure 2 Cripto-1 is a target gene in a canonical Wnt3/b-catenin/ Lef-1 (Tcf) signaling pathway and also a coreceptor for Wnt and glypican-1. Wnt3 binds to a frizzled (Frz) receptor and coreceptors LRP5/6 and Cripto-1. Activation of Dishevelled (Dsh) results in the inactivation of the b-catenin degradation complex (GSK-3b/ Axin/Apc), which promotes ubiquination and proteosomal degradation of b-catenin. b-Catenin accumulates and can bind to the DNA-binding proteins of the transcription factor family Lef-1/Tcf after translocation to the nucleus. Cripto-1 and glypican-4 can also function as coreceptors for Wnts such as Wnt5A with Frz to activate the planar cell polarity pathway (PCP). This pathway is also regulated through Dsh which can stimulate RhoA/ROCK and Rac/JNK to activate the transcription factor c-Jun and components of the cytoskeleton and cell motility. Finally, Cripto-1 can bind to glypican-1 in lipid rafts and activate c-src which can then enhance the ras/MAPK and/or PI-3 kinase/Akt pathways. PI3K/ Akt signaling molecules are also known to be capable of inactivating GSK-3b causing similar cellular modifications that occur during Wnt signaling Cripto-1: a modulator during embryogenesis and oncogenesis L Strizzi et al differentiation. However, the effects of Cripto-1 observed in vitro may depend on the type of cells used and their responsiveness to variations in growth conditions, reflecting the fact that the mammary gland epithelium cyclically goes through phases of proliferation and involution depending on the variable levels of growth factors and hormones present in the environment in which they grow. For instance, normal HC-11 cells cultured in low serum and treated with CR-1 show an increase in apoptosis through activation of caspase-3 protease and downregulation of expression of the antiapoptotic protein Bcl-xl (De .
Cripto-1 is upregulated in transgenic mouse mammary tumors
Transgenic mice overexpressing either neu (erbB-2), TGF-a, int-3, polyoma middle T (PyMT) or simian virus 40 large T antigens have been shown to develop mammary gland tumors (Jhappan et al., 1990 (Jhappan et al., , 1992 Guy et al., 1992; Maroulakou et al., 1994; Muller et al., 1998) . All of these tumors were found to express significant levels of Cr-1 mRNA and protein as determined by RT-PCR, Western blot analysis and immunohistochemistry (Kenney et al., 1996) . In addition to expression in mammary gland tumors of transgenic mice, Cr-1 was also consistently expressed in hyperplastic lesions in mammary glands of PyMT, neu and TGF-a mouse transgenic models suggesting a role for Cr-1 in deregulation of mammary epithelial proliferation (Niemeyer et al., 1999) . The insertion of Elvax pellets containing the EGF-like motif of CR-1 protein into the mammary gland of ovariectomized virgin mice produced a dramatic increase in DNA synthesis in mammary epithelial cells immediately adjacent to the pellets . In addition, increased ductal branching and hyperplasia was observed when FVB/N or C57B1/6 mouse mammary epithelial cells, containing retroviral-driven overexpression of Cr-1 cDNA, were subsequently transplanted into cleared mammary fat pad of syngenic ovariectomized virgin mice . Although mammary carcinomas were not observed to arise from the transplanted hyperplasias, the hyperplasias could be serially transplanted, suggesting the presence of a Cr-1-induced immortalized population of mammary epithelial cells. Similarly, when NOG-8 or CID-9 Cripto-1-transformed cells were subsequently transplanted in vivo, these cells were unable to form tumors Niemeyer et al., 1998) . This suggests that other genetic alterations must take place in addition to Cripto-1 overexpression for tumors to develop.
In vivo tumorigenesis induced by Cripto-1
The first in vivo study that showed CR-1-dependent hyperplasia and tumor growth in mouse mammary glands used the mouse mammary tumor virus (MMTV) to drive CR-1 overexpression . Virgin MMTV-CR-1 transgenic mice exhibited enhanced ductal branching and dilatation, intraductal hyperplasia and hyperplastic alveolar nodules. Mammary glands from 12-to 20-month-old multiparous MMTV-CR-1 mice showed multifocal hyperplasias and approximately 33% of these mice subsequently developed papillary adenocarcinomas (Figure 3) . The long latency period suggests that additional genetic alterations are required to facilitate mammary tumor formation in conjunction with CR-1. The WAP promoter can be used to drive high levels of transgene expression in a significantly greater number of mammary epithelial cells, predominantly during pregnancy and lactation (Kordon et al., 1995) . This allows assessment of any significant effect on mammary gland development or formation of premalignant or malignant lesions in the pregnant and lactating mammary gland of multiparous mice. Mice expressing the human CR-1 transgene under the regulation of the WAP promoter in FVB/N mice have been recently developed (Sun et al., 2005, submitted) . Higher levels of phosphorylated AKT and MAPK were detected in mammary glands of multiparous WAP-CR-1 mice as compared to multiparous FVB/N mice, suggesting increased cell proliferation and survival of the transgenic mammary gland. In addition, over half of the WAP-CR-1 multiparous female mice developed multifocal mammary tumors of mixed histological subtypes. These tumors were histologically distinct from the mammary tumors that developed in the MMTV-CR-1 transgenic mouse. The mammary tumors from the WAP-CR-1 mice contained foci of epithelial hyperplasia mixed with glandular, papillary and solid carcinomas. Areas of adenosquamous and myoepithelial differentiation were also identified within these tumors (Figure 4) . These tumors were similar to the mixed histotype of mammary tumors that arise in (Miyoshi et al., 2002a, b; Rosner et al., 2002; Li et al., 2003; Teuliere et al., 2005) . In fact, increased expression of dephosphorylated b-catenin in WAP-CR-1 mammary tumors suggests that a canonical Wnt signaling pathway may be activated in these tumors. In addition, as described for Wnt pathway mammary tumors (Miyoshi et al., 2002a) , evidence of epidermal transdifferentiation, as determined by positive immunostaining for the epidermal cell cytokeratins CK-1 and CK-6 and for hair and nail cytokeratin, AE-13 (Weiss et al., 1984; Fuchs and Byrne, 1994) was also found in the mammary tumors from the WAP-CR-1 transgenic mice. These results demonstrate that overexpression of CR-1 during pregnancy and lactation can lead to the development of mammary tumors in multiparous mice and that CR-1 may be a significant mediator of some of the oncological effects of an activated canonical Wnt signaling pathway in the mammary gland.
Expression of Cripto-1 in human carcinomas and premalignant lesions
Expression of CR-1 mRNA and/or immunoreactive protein has been demonstrated to occur with high frequency in colorectal, breast, ovarian and gastric cancers in different studies that have examined a relevant number of tumor specimens (Kuniyasu et al., 1991; Saeki et al., 1992 Saeki et al., , 1994a Qi et al., 1994; Stromberg et al., 1994; Normanno et al., 1995; Panico et al., 1996; Niikura et al., 1997; De Angelis et al., 1999; D'Antonio et al., 2002) . Expression of CR-1 in normal tissues has been examined in some of these studies. CR-1 protein is usually expressed with low frequency and at low levels in normal mucosae, whereas an increase in CR-1 expression has been observed in the normal mucosa adjacent to either colon or breast carcinoma (Saeki et al., 1992; Panico et al., 1996) . Furthermore, CR-1 expression is significantly increased in premalignant lesions, such as colon adenomas, intestinal metaplasia of the gastric mucosa and ductal carcinoma in situ (DCIS) of the breast. In this respect, the frequency of CR-1 expression in the adenomas was found to correlate directly with the degree of dysplasia, and with the size and the histological subtype of colon adenomas (Saeki et al., 1994b) . CR-1 expression was also detected in 62% of normal colon mucosa specimens from individuals that belong to families with a high incidence of colorectal carcinomas, whereas only 20% of colon mucosa from low-risk patient specimens was positive for CR-1 (De Angelis et al., 1999) . In an additional study, expression of CR-1 immunoreactivity in normal rectal mucosa adjacent to carcinoma was associated with an increase in the incidence of bowel wall penetration, lymph node involvement and a recurrence rate of 100% (Gagliardi et al., 1994) . Therefore, the gradual increase in CR-1 expression that occurs in the multistage process that evolves from normal mucosa to premalignant lesions, and from premalignant lesions to carcinoma, suggests that CR-1 may be involved in the early events of carcinogenesis in different tissues. Although no significant correlations have been found between CR-1 expression and patient prognosis in human carcinomas, several findings suggest that CR-1 has an important role in tumor progression. For example, a statistically significant higher expression of CR-1 was found in extra-ovarian specimens as compared with ovarian primary tumors, in a subset of patients for which both type of tissues were available (D'Antonio et al., 2002) . This observation suggests that overexpression of CR-1 might be associated with an increased ability to form metastasis. This hypothesis is in agreement with recent in vitro findings discussed above that have demonstrated that expression of CR-1 is associated with increased motility and invasiveness of tumor cells Bianco et al., 2003; Normanno et al., 2004; Strizzi et al., 2004) . Interestingly, CR-1 is frequently coexpressed with other EGF-related peptides, such as TGF-b, amphiregulin and heregulin in human breast and mouse epidermal carcinomas, implying that different growth factors might cooperate in supporting the autonomous proliferation of cancer cells (Saeki et al., 1992; Qi et al., 1994; Normanno et al., 1995; Panico et al., 1996; De Angelis et al., 1999; D'Antonio et al., 2002; Liu et al., 2003) . Finally, expression of CR-1 has been reported in other carcinoma types, including lung carcinoma (Fontanini et al., 1998) , nonseminomatous testicular tumors (Baldassarre et al., 1997) , pancreatic ductal adenocarcinoma (Friess et al., 1994; Tsutsumi et al., 1994) , basal cell carcinoma (Welss et al., 2003) and bladder carcinoma (Byrne et al., 1998) . Recently, mouse Cr-1 and human CR-1 have been identified as direct target genes in a canonical Wnt/bcatenin/Tcf signaling pathway (Morkel et al., 2003) . Cr-1 expression was found to be downregulated in either b-catenin À/À or Wnt3
À/À mutant mouse embryos, whereas a constitutively active form of b-catenin was able to upregulate Cr-1 expression during early embryogenesis. Likewise in Apc À/À Min mice, Cr-1 expression was elevated in intestinal adenomas that develop in these postnatal mice. Reciprocally, in human colon carcinoma cells that express high levels of CR-1, induction of a dominant-negative Tcf4 abolished CR-1 expression. Therefore, in contrast to transient activation of Wnts and Cripto-1 which is obligatory for the promotion of stem cell self-renewal, pluripotency and fixation of stem cell identity in ES cells and in stem cells from normal adult tissues of the haematopoietic system, skin, central nervous system, pancreas, intestine and breast (Beachy et al., 2004; Besser, 2004; Kanatsu-Shinohara et al., 2004; Kleber and Sommer, 2004; Nelson and Nusse, 2004; Sato et al., 2004; Zhang et al., 2004; James et al., 2005; Wei et al., 2005) , continuous activation of these genes is associated with the initiation and/or progression of cancer in mouse and human tissues such as in the hematopoietic system, skin, colon, stomach, liver, ovary and breast (Polakis, 2000; Salomon et al., 2000) . In addition to being a direct target gene in a canonical Wnt signaling pathway, in Xenopus, the Cripto-1 ortholog, FRL1 functions as a coreceptor through the EGF-like domain and the juxtamembrane region for Wnt11 in conjunction with the frizzled receptor Xfz7 and glypican-4 to activate a canonical Wnt pathway that is dependent upon b-catenin and that is necessary for dorsal axis specification during early embryogenesis (Tao et al., 2005) . Finally, Wnt8c and b-catenin, which are expressed in Hensens node and which regulate L/R axis formation in the chick, are able to directly induce Nodal expression (Rodriguez-Esteban et al., 2001) .
In addition to maintaining stem cell identity, other significant biological activities that are shared by Wnts and Cripto-1 are their ability to stimulate cell motility, invasion and EMT, as previously discussed in this review Bianco et al., 2003; Kemler et al., 2004; Strizzi et al., 2004; Endo et al., 2005; Yook et al., 2005) . Loss of cell-cell adhesion due to a reduction in E-cadherin expression, possibly through Wnt/Cripto-1 crosstalk, may also affect the integrity of the stem cell niche since cell adhesion between supporting niche cells and stem cells is required for stem cell survival and asymmetric cell division (Matsui and Okamura, 2005; Yamashita et al., 2005) . Reciprocally, a loss of cell-cell adhesion due to a repression of E-cadherin expression may also be important for the movement of differentiated intestinal and skin epithelial cells from the niche as occurs in the intestinal crypts and in the bulge region of the papillae of the hair follicles. In addition, in the intestinal epithelium, expression of guidance proteins such as, the Wnt target gene EphB3, is also necessary for directing migration of the Paneth cells out of and down from the crypts (Batlle et al., 2002; Escaffit et al., 2005) .
